RPRX Royalty Pharma plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802768 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.4%
TTM net income YoY-12.1%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR4.0%
Net income 3-yr CAGR53.8%
Margins
Gross margin—
Operating margin57.1%
Net margin25.7%
FCF margin—
EBITDA margin57.3%
Returns
ROE10.1%
ROA3.5%
ROIC (approx.)10.2%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity1.26x
Current ratio1.29x
Interest coverage4.02x
Cash quality & payout
Operating cash flow / net income4.41x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| R&D expense | $452.00M | $2.00M | $52.00M | $177.11M | $200.08M |
| SG&A expense | $573.48M | $236.67M | $249.75M | $227.30M | $182.83M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B |
| Interest expense | $307.66M | $225.51M | $187.19M | $187.96M | $166.14M |
| Pretax income | $1.32B | $1.33B | $1.70B | $230.06M | $1.24B |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M |
| EBITDA | $1.56B | $1.29B | $1.49B | — | — |
| EPS (basic) | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 |
| EPS (diluted) | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 |
| Dividends declared per share | — | 0.84 | 0.80 | 0.76 | 0.68 |
| Weighted avg. shares (diluted) | 564.46M | 594.11M | 602.90M | 437.97M | 414.80M |
| Banking | |||||
| Provision for credit losses | — | — | — | — | $452.84M |
| Balance sheet | |||||
| Cash & equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B |
| Short-term investments | $18.80M | $58.20M | $18.30M | $1.30M | $66.00M |
| Current assets | $1.53B | $1.80B | $1.27B | $2.55B | $2.88B |
| Goodwill | $924.63M | $0 | — | — | — |
| Intangibles | — | — | — | $0 | $5.67M |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B |
| Current liabilities | $636.21M | $1.25B | $161.38M | $1.17B | $171.25M |
| Short-term debt | $380.00M | $997.77M | $0 | $997.51M | $0 |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B |
| Total debt | $8.95B | $7.61B | $6.14B | $7.12B | $7.10B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B |
| Shareholders' equity | $6.48B | $6.95B | $6.53B | $5.63B | $5.78B |
| Net debt | $8.33B | $6.68B | $5.66B | $5.41B | $5.56B |
| Cash flow statement | |||||
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | -$1.87B |
| Financing cash flow | -$1.19B | $361.14M | -$2.15B | -$944.86M | $385.11M |
| Depreciation & amortization | $3.85M | $0 | $0 | — | — |
| Stock-based compensation | $289.89M | $2.34M | $2.36M | $2.17M | $2.44M |
| Share buybacks | $1.23B | $229.65M | $304.76M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.